Skip to main navigation

Investor Relations

Overview
Stock Information
News & Events
Financial Information
Corporate Governance
Shareholder Services

Presentations & Publications

Corporate Presentations

Corporate Presentation - September 2023

Sep 08, 2023

Data & Congress Presentations

IMPORT-201 (IMP-MEL): A Phase 1 first-in-human dose finding/randomized Phase 2 study of a novel iNKT agonist (PORT-2) and pembrolizumab for advanced melanoma and non-small cell lung cancer (NSCLC)

November 4, 2023

Source

Presented at SITC 2022

AADPORT-601 (TT-10-101): First-in-Human Study of Adenosine 2A (A2A) and Adenosine 2B (A2B) receptor antagonists in Participants with Selected Advanced Solid Tumors

November 3, 2023

Source

Presented at SITC 2022

A phase 1 first-in-human dose finding/randomized phase 2 study of IMM60 and pembrolizumab in advanced melanoma and NSCLC (IMP-MEL)

June 26, 2023

Source

Presented at ASCO 2023

IMP-MEL: A phase 1 first-in-human dose-finding study of a novel invariant natural killer T-cell agonist (iNKT) IMM60 in advanced melanoma and non-small-cell lung cancer (NSCLC)

November 10, 2022

Source

Presented at SITC 2022

A phase 1 first-in-human dose finding/randomized phase 2 study of IMM60 and pembrolizumab (PEM) in advanced melanoma and NSCLC (IMP-MEL)

October 3, 2022

Source

Presented at ASCO 2022

Early Results of Intratumoral INT230-6 Alone or in Combination with Ipilimumab in Subjects with Advanced Sarcomas

July 21, 2022

Source

Presented at ASCO 2021

A Phase 1/2 study of Intratumoral INT230-6 Alone (IT-01) or in Combination with Pembrolizumab [KEYNOTE-A10] in Adult Subjects with Locally Advanced, Unresectable and Metastatic Solid Tumors Refractory to Therapy

July 21, 2022

Source

Presented at ASCO 2021

Publications

Co-delivery of PLGA Encapsulated Invariant NKT Cell Agonist with Antigenic Protein Induce Strong T Cell-Mediated Antitumor Immune Responses

PLGA Nanoparticles Co-encapsulating NY-ESO-1Peptides and IMM60 Induce Robust CD8 and CD4 T Cell and B Cell Responses

Intratumoral Administration of a Novel Cytotoxic Formulation with Strong Tissue Dispersive Properties Regresses Tumor Growth and Elicits Systemic Adaptive Immunity in In Vivo Models

Featured Pages

Stock Information

Financial Information

Investor Tools

Print Page
RSS Feeds
Email Page
Email Alerts

Request Email Alerts

Copyright © All rights reserved Portage Biotech

Legal Links

Terms of Use Privacy policy Disclaimer

Facebook
Twitter
LinkedIn
Google+